Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Inventory: 2017-2025

Historic Inventory for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $52.2 million.

  • Ultragenyx Pharmaceutical's Inventory rose 20.46% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 20.46%. This contributed to the annual value of $45.0 million for FY2024, which is 32.49% up from last year.
  • Ultragenyx Pharmaceutical's Inventory amounted to $52.2 million in Q3 2025, which was up 12.26% from $46.5 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Inventory peaked at $52.2 million during Q3 2025, and registered a low of $12.5 million during Q1 2021.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Inventory value was $40.1 million (recorded in 2024), while the average stood at $39.1 million.
  • Data for Ultragenyx Pharmaceutical's Inventory shows a peak YoY skyrocketed of 64.91% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Inventory stood at $16.2 million in 2021, then spiked by 64.91% to $26.8 million in 2022, then rose by 26.91% to $34.0 million in 2023, then skyrocketed by 32.49% to $45.0 million in 2024, then grew by 20.46% to $52.2 million in 2025.
  • Its Inventory stands at $52.2 million for Q3 2025, versus $46.5 million for Q2 2025 and $46.0 million for Q1 2025.